Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209009 | 1.00 | LMNA (0.50) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL10245268 | 1.00 | LMNA (0.50) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL437046 | 0.86 | LMNA (0.38) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL3954367 | 0.83 | LMNA (0.33) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL10245473 | 0.80 | TSHR (0.39) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL10246425 | 0.80 | TSHR (0.39) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL10246446 | 0.80 | TSHR (0.39) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL21371585 | 0.78 | LMNA (0.31) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL26306505 | 0.77 | LMNA (0.48) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL14266734 | 0.77 | ALDH1A1 (0.41) | LMNACNR1ADRA1ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3903909-B1 | REMOVAL OF HYDROGEN SULPHIDE AND CARBON DIOXIDE FROM A FLUID FLOW | BASF SE (DE) | 2024-06-19 | — | — | EP | disclosed |
| US-11278841-B2 | Removal of hydrogen sulphide and carbon dioxide from a stream of fluid | BASF SE (DE) | 2022-03-22 | — | — | US | disclosed |
| EP-3903909-A1 | REMOVAL OF HYDROGEN SULPHIDE AND CARBON DIOXIDE FROM A FLUID FLOW | BASF SE (DE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3185989-B1 | REMOVAL OF HYDROGEN SULPHIDE AND CARBON DIOXIDE FROM A STREAM OF FLUID | BASF SE (DE) | 2021-08-11 | — | — | EP | disclosed |
| CN-106794414-B | Removal of hydrogen sulfide and carbon dioxide from fluid streams | 巴斯夫欧洲公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190134557-A1 | REMOVAL OF HYDROGEN SULPHIDE AND CARBON DIOXIDE FROM A STREAM OF FLUID | BASF SE (DE) | 2019-05-09 | — | — | US | disclosed |
| US-10207217-B2 | Removal of hydrogen sulphide and carbon dioxide from a stream of fluid | BASF SE (DE) | 2019-02-19 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170282115-A1 | REMOVAL OF HYDROGEN SULPHIDE AND CARBON DIOXIDE FROM A STREAM OF FLUID | BASF SE (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2015-05-28 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| EP-1401443-A4 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORP (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040147739-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| EP-1401443-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098424-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | LMNA 1681/4885CNR1 31/4885ADRA1A 106/4885 |
| US-20170282115-A1 | REMOVAL OF HYDROGEN SULPHIDE AND CARBON DIOXIDE FROM A STREAM OF FLUID | C1R, MSRB3, HRH4 | LMNA 4861/4885CNR1 18/4885ADRA1A 1842/4885 |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | LMNA 3690/4885CNR1 13/4885ADRA1A 100/4885 |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD7, BRD3 | LMNA 1213/4885CNR1 438/4885ADRA1A 2582/4885 |
| US-20040147739-A1 | Novel anti-infectives | RPL5, RPL7, RPL35 | LMNA 4806/4885CNR1 2864/4885ADRA1A 3690/4885 |
| US-11278841-B2 | Removal of hydrogen sulphide and carbon dioxide from a stream of fluid | C1R, MSRB3, HRH4 | LMNA 4860/4885CNR1 18/4885ADRA1A 1851/4885 |
| US-10207217-B2 | Removal of hydrogen sulphide and carbon dioxide from a stream of fluid | C1R, MSRB3, HRH4 | LMNA 4861/4885CNR1 18/4885ADRA1A 1842/4885 |
| US-20190134557-A1 | REMOVAL OF HYDROGEN SULPHIDE AND CARBON DIOXIDE FROM A STREAM OF FLUID | C1R, MSRB3, HRH4 | LMNA 4861/4885CNR1 18/4885ADRA1A 1842/4885 |
| US-10519160-B2 | Imaging agents for neural flux | SLC18A2, SLC18A3, PMP22 | LMNA 2315/4885CNR1 122/4885ADRA1A 1623/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | LMNA 1467/4885CNR1 4356/4885ADRA1A 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.